Cabaletta Bio, Inc. SEC filings CABA
Cabaletta Bio, Inc. has 448 filings in SEC EDGAR's recent list, going back to Dec 10, 2018. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 9, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 9, 2026 |
| DEF 14A | Proxy statement | May 13, 2025 | Jun 9, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 30, 2025 | Jun 9, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 3, 2024 |
| DEFA14A | Additional proxy material | Apr 21, 2023 | — |
| DEF 14A | Proxy statement | Apr 21, 2023 | Jun 1, 2023 |
| DEFA14A | Additional proxy material | Apr 21, 2022 | — |
| DEF 14A | Proxy statement | Apr 21, 2022 | Jun 1, 2022 |
| DEFA14A | Additional proxy material | Apr 21, 2021 | — |
| DEF 14A | Proxy statement | Apr 21, 2021 | Jun 1, 2021 |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 2, 2020 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CABA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1759138
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.